Research Calls
- Upgrades:
- Avery Dennison (AVY) upgraded to Overweight from Neutral at JP Morgan; tgt lowered to $195
- Ares Capital (ARCC) upgraded to Overweight from Neutral at JP Morgan; tgt $22
- Brookfield Asset Mgmt (BAM) upgraded to Outperform from Neutral at Credit Suisse; tgt raised to $71.50
- Ecolab (ECL) upgraded to Overweight from Neutral at JP Morgan; tgt lowered to $190
- Estee Lauder (EL) upgraded to Buy from Hold at Edward Jones
- Franklin Electric (FELE) upgraded to Buy from Neutral at Seaport Research Partners
- Halliburton (HAL) upgraded to Buy from Hold at HSBC Securities; tgt raised to $41.60
- Robert Half (RHI) upgraded to Buy from Neutral at BofA Securities; tgt raised to $133
- Rush Street Interactive (RSI) upgraded to Overweight from Equal Weight at Wells Fargo; tgt $10
- Schlumberger (SLB) upgraded to Buy from Hold at HSBC Securities; tgt raised to $44.20
- Downgrades:
- BNY Mellon (BK) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $51.50
- Capital One (COF) downgraded to Neutral from Overweight at Piper Sandler; tgt lowered to $143
- Robert Half (RHI) upgraded to Buy from Neutral at BofA Securities; tgt raised to $133
- Euronav (EURN) downgraded to Hold from Buy at Jefferies; tgt lowered to $12
- JetBlue Airways (JBLU) downgraded to Underweight from Overweight at JP Morgan; tgt lowered to $12
- Molecular Partners AG (MOLN) downgraded to Neutral from Buy at Kempen; tgt $10
- Molecular Partners AG (MOLN) downgraded to Underperform from Neutral at Credit Suisse
- PotlatchDeltic (PCH) downgraded to Sector Perform from Outperform at RBC Capital Mkts; tgt lowered to $60
- SkyWest (SKYW) downgraded to Mkt Perform from Outperform at Raymond James
- Others:
- Appian (APPN) initiated with a Buy at Goldman; tgt $70
- Aecom Tech (ACM) initiated with an Outperform at RBC Capital Mkts; tgt $91
- Aldeyra Therapeutics (ALDX) assumed with a Buy at H.C. Wainwright; tgt $15
- Cazoo (CZOO) initiated with a Neutral at UBS; tgt $2.60
- Insmed (INSM) initiated with a Buy at Goldman; tgt $56
- Jacobs Engineering (J) initiated with an Outperform at RBC Capital Mkts; tgt $173
- Organon (OGN) initiated with a Buy at Goldman; tgt $40
- Royalty Pharma (RPRX) initiated with a Buy at Goldman; tgt $56
- UroGen Pharma (URGN) initiated with a Buy at Berenberg; tgt $20
- Vor Biopharma (VOR) initiated with a Neutral at Goldman; tgt $6
- WalkMe Ltd. (WKME) initiated with a Buy at Goldman; tgt $23
- Warner Bros. Discovery (WBD) initiated with an Equal Weight at Barclays; tgt $24